Drugs / benzathine benzylpenicillin G
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04838717 | Dec 2021 → Jul 2025 | syphilis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07146048 Comparator | Mar 2026 → Feb 2029 expected | rheumatic heart disease | Children's Hospital Medical Center, Cincinnati | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | benzathine benzylpenicillin G | “single intramuscular injection of 2.4 million units of benzathine benzylpenicillin G (BPG)” NCT04838717 ↗1“The control arm will receive intramuscular benzathine benzylpenicillin G (BPG) prophylaxis” NCT07146048 ↗ |
| Known as | BPG | “single intramuscular injection of 2.4 million units of benzathine benzylpenicillin G (BPG)” NCT04838717 ↗1“The control arm will receive intramuscular benzathine benzylpenicillin G (BPG) prophylaxis” NCT07146048 ↗ |
| Route | Intramuscular | “intramuscular injection of 2.4 million units” NCT04838717 ↗ |